Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

KRAS G12C is one of several genetic mutations known to activate the KRAS protein, which drives tumor growth and progression. KRAS mutations are present in up to 45% of colorectal cancer cases, but ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein ...

Credit: Canadian Light Source The researchers found that when the Ras protein is in its mutated, cancer-causing state, "molecules snuggle inside the pocket. Using crystallography, we were able to ...

The KRAS G12D mutation is the most common oncogenic KRAS variant, identified in approximately 34% of pancreatic ductal adenocarcinoma cases, 12% of colorectal cancers and 4% of lung adenocarcinomas.

In a recent paper published in Nature, researchers from the University of Michigan have discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and ...

KRAS G12C is one of several genetic mutations that are known to activate the KRAS protein, which drives tumor growth and progression. KRAS mutations are present in up to 45% of colorectal cancer ...